Description
About Canmab: Canmab is a groundbreaking pharmaceutical product manufactured by Biocon Pharma Ltd. It is a highly potent and effective medication primarily used in the treatment of certain types of cancer, particularly breast cancer that overexpresses the HER2 protein. Trastuzumab, the active ingredient in Canmab, is a monoclonal antibody that targets and inhibits the HER2 protein, thereby slowing down the growth and spread of cancer cells.
Key Features:
- High Efficacy: Canmab is formulated to provide maximum efficacy in combating HER2-positive breast cancer, offering patients a robust treatment option.
- Trastuzumab 440 Mg Injection: Each vial of Canmab contains 440 mg of Trastuzumab, ensuring potent and precise dosing for optimal therapeutic outcomes.
- Precision Medicine: Canmab exemplifies precision medicine by specifically targeting cancer cells that overexpress the HER2 protein, minimizing damage to healthy tissues and reducing side effects.
- Quality Assurance: Manufactured by Biocon Pharma Ltd., Canmab adheres to the highest quality standards, ensuring safety, purity, and efficacy in every dose.
- Clinically Proven: Canmab’s efficacy and safety profile are backed by extensive clinical trials, making it a trusted choice for oncologists and patients worldwide.
- Easy Administration: Canmab is designed for convenient administration through intravenous injection, facilitating seamless integration into treatment regimens.
Indications: Canmab is indicated for the treatment of:
- HER2-positive breast cancer, either as monotherapy or in combination with other anticancer therapies.
Usage Directions: Canmab should be administered under the supervision of a qualified healthcare professional experienced in the use of cancer chemotherapeutic agents. The dosage and duration of treatment may vary depending on individual patient factors and the stage of cancer. It is crucial to follow the prescribing physician’s instructions and adhere to the recommended dosing schedule.
Storage Information:
- Store Canmab vials in the original packaging at controlled room temperature (20°C to 25°C).
- Protect from light and moisture.
- Do not freeze.
- Keep out of reach of children and pets.
Caution:
- Canmab is contraindicated in patients with known hypersensitivity to Trastuzumab or any of the excipients in the formulation.
- Serious cardiotoxicity, infusion reactions, and pulmonary toxicity have been reported with the use of Trastuzumab. Close monitoring of cardiac function and vital signs is recommended during treatment.
Availability: Canmab (Trastuzumab 440 Mg Injection) is available by prescription only and can be obtained from authorized healthcare facilities and pharmacies.
Disclaimer: The information provided herein is for informational purposes only and should not be construed as medical advice or a substitute for professional medical consultation. Patients should consult their healthcare providers regarding diagnosis, treatment, and potential side effects associated with Canmab therapy.
Reviews
There are no reviews yet.